IRON Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.702

+73.64%

-1.779

+74.37%

-1.616

+2.26%

Estimates Revision

The market is revising Upward the revenue expectations for Disc Medicine, Inc. (IRON) for FY2026, with the revenue forecasts being adjusted by 47.33% over the past three months. During the same period, the stock price has changed by 52.65%.

Revenue Estimates for FY2026

Revise Upward

+47.33%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+7.24%

In Past 3 Month

Stock Price

Go Up

+52.65%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast IRON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRON is 114.91 USD with a low forecast of 91.00 USD and a high forecast of 153.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

0 Hold

0 Sell

Strong Buy

Current: 91.250

Low

91.00

Averages

114.91

High

153.00

Current: 91.250

Low

91.00

Averages

114.91

High

153.00

Truist

Buy

maintain

$86 -> $114

2025-11-10

Reason

Truist

Price Target

$86 -> $114

2025-11-10

maintain

Buy

Reason

Truist raised the firm's price target on Disc Medicine to $114 from $86 and keeps a Buy rating on the shares. The firm is updating its model to incorporate Disc's Q3 financial results, the full U.S. bitopertin opportunity in EPP, and an accelerated launch timeline following receipt of the FDA Commissioner's priority review vouchers, the analyst tells investors in a research note.

Stifel

Stephen Willey

resume

$125

2025-11-03

Reason

Stifel

Stephen Willey

Price Target

$125

2025-11-03

resume

Reason

Stifel analyst Stephen Willey resumed coverage of Disc Medicine with a Buy rating and $125 price target. The firm believes the company's clinical-stage portfolio of assets targeting heme biosynthesis and iron bioavailability will prove clinically and commercially relevant across a broad spectrum of hematological disorders, the analyst tells investors. The firm believes the CNPV-accelerated commercialization of bitopertin in erythropoietic and X-linked protoporphyria and favorable confirmatory Phase 3 APOLLO trial prospects "create a clear path to longer-term profitability," the analyst added.

Wedbush

David Nierengarten

Outperform

upgrade

$90 -> $110

2025-10-17

Reason

Wedbush

David Nierengarten

Price Target

$90 -> $110

2025-10-17

upgrade

Outperform

Reason

Wedbush analyst David Nierengarten raised the firm's price target on Disc Medicine to $110 from $90 and keeps an Outperform rating on the shares. The firm notes the company received a Commissioner's National Priority Voucher, reducing drug application review time for bitopertin to 1-2 months. Wedbush expects FDA to decide on Priority Review for bitopertin in EPP/XLP in late November/early December based on a September 30 NDA submission, which could imply regulatory approval by early February 2026.

Raymond James

Strong Buy

maintain

$89 -> $108

2025-10-17

Reason

Raymond James

Price Target

$89 -> $108

2025-10-17

maintain

Strong Buy

Reason

Raymond James raised the firm's price target on Disc Medicine to $108 from $89 and keeps a Strong Buy rating on the shares. The announcement that bitopertin is among the first cohort of drugs to receive the FDA Commissioner's National Priority Voucher is highly positive, potentially accelerating the bitopertin launch in EPP by more than a quarter, and further increasing the firm's confidence in the prospects for accelerated approval, the analyst tells investors in a research note.

Cantor Fitzgerald

NULL -> Overweight

maintain

$132 -> $153

2025-10-17

Reason

Cantor Fitzgerald

Price Target

$132 -> $153

2025-10-17

maintain

NULL -> Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Disc Medicine to $153 from $132 and keeps an Overweight rating on the shares. Disc Medicine announced it was one of the initial recipients of FDA Commissioner's National Priority Voucher for bitopertin in erythropoietic protoporphyria, the analyst tells investors in a research note. A key advantage is that there is a higher likelihood of approval, the firm says.

Truist

initiated

$86

2025-07-21

Reason

Truist

Price Target

$86

2025-07-21

initiated

Reason

Truist initiated coverage of Disc Medicine with a Buy rating and $86 price target. Disc Medicine is a compelling stock to own due to key value drivers that include lead de-risked asset, bitopertin in rare genetic disorder erythropoietic protoporphyria, potential blockbuster anemia agent, DISC-0974, and DISC-3405 in blood disorder polycythemia vera, the analyst tells investors in a research note. The firm sees significant upside potential by the second half of 2026 for accelerated approval of bito, and positive confirmatory data by early-27, and also thinks risk/reward for 0974 is favorable with large upside potential.

Valuation Metrics

The current forward P/E ratio for Disc Medicine Inc (IRON.O) is -14.22, compared to its 5-year average forward P/E of -11.00. For a more detailed relative valuation and DCF analysis to assess Disc Medicine Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.00

Current PE

-14.22

Overvalued PE

-7.95

Undervalued PE

-14.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.91

Current EV/EBITDA

-12.08

Overvalued EV/EBITDA

-4.85

Undervalued EV/EBITDA

-8.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

471.70

Current PS

195.58

Overvalued PS

2073.32

Undervalued PS

-1129.91

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IRON News & Events

Events Timeline

No data

News

2.0

12-06Globenewswire

Disc Medicine Reports Positive Initial Data for DISC-0974 in MF Anemia Treatment

1.0

10-31Newsfilter

Disc Medicine to Attend Upcoming Investor Conferences

4.0

10-23TipRanks

Three Stocks Boasting a Perfect 10 Smart Score and Strong Buy Consensus

People Also Watch

Frequently Asked Questions

What is Disc Medicine Inc (IRON) stock price today?

The current price of IRON is 91.25 USD — it has decreased -0.65 % in the last trading day.

What is Disc Medicine Inc (IRON)'s business?

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

What is the price predicton of IRON Stock?

What is Disc Medicine Inc (IRON)'s revenue for the last quarter?

Disc Medicine Inc revenue for the last quarter amounts to -67.70M USD, increased 106.04 % YoY.

What is Disc Medicine Inc (IRON)'s earnings per share (EPS) for the last quarter?

Disc Medicine Inc. EPS for the last quarter amounts to -47825000.00 USD, increased 175.47 % YoY.

What changes have occurred in the market's expectations for Disc Medicine Inc (IRON)'s fundamentals?

How many employees does Disc Medicine Inc (IRON). have?

Disc Medicine Inc (IRON) has 84 emplpoyees as of December 15 2025.

What is Disc Medicine Inc (IRON) market cap?

Today IRON has the market capitalization of 3.47B USD.